Trial failure for Jazz’s cannabis-derived drug blunts goal to expand its use to US

Jazz Pharmaceuticals made its cannabis drug ambitions clear last year with a $7.2 billion acquisition of GW Pharmaceuticals and again in March when it started building a plant in the U.K. designed specifically for cannabis-based medicines.